• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [20545 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Detecting COPD in persons over 50 years with persistent cough in general practice: comparison of cost-effectiveness of diagnostic strategies]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [DETECTA-T]
2011     Health Intervention and Technology Assessment Program (HITAP) [Designing a decision frame for making health resource allocation decisions: a case study in Thailand]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Design of an interaction protocol between Primary Care and Hospitals to improve early detection and monitoring of patients with multiple sclerosis]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Design and validation of a screening tool for evaluating the health impact of regional policies]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Design and implementation plan of telemedicine in specific clinical areas: telemonitoring and teledermatology. Assessment of initial results and costs]
2021     Center for Drug Evaluation (CDE) [Descriptive study and comparative effectiveness of listed medications for osteoporosis on new osteoporotic fracture event in osteoporosis patients by using National Health Insurance claim database]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Description of the use of Proton Pump Inhibitors (PPIs) in adults covered by the public prescription drug insurance plan]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Description of the elaboration of a clinical practice guidelines for asthma in the autonomous community of the Basque country by means of a mixed method of adaptation-development-actualization]
2021     Norwegian Institute of Public Health (NIPH) [Description and quality assessment of guidelines for tonsillectomy in patients with recurrent tonsillitis: mapping review]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Descemet Stripping Automated Endothelial Keratoplasty (DSAEK) for corneal endothelial dysfunction]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Depression in chronically ill elderly]
2009     Haute Autorite de sante (HAS) [Dental prostheses with ceramic and/or milled cores (full assessment)]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Dental indications for standardised procedures of instrumental functional analysis under consideration of health economic aspects]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Dental indications for standardised procedures of instrumental functional analysis under consideration of health economic aspects]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Denosumab for the treatment of solid tumor bone metástasis]
2008     Andalusian Health Technology Assessment Area (AETSA) [Denaturing high performance liquid chromatography (DHPLC). Use and utility in massive genotyping]
2011     Committee for New Health Technology Assessment (CNHTA) [Deletion of 18q choromosome in colorectal cancer (LOH, loss of heterozygosity)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Delamanid (pulmonary multi-drug resistant tuberculosis, body weight >= 10 kg) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Defibrillators in public places]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Deferred parathyroid autograft with cryopreserved tissue for the surgical management of hyperparathyroidism]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Deep brain stimulation using electrodes in the treatment of Parkinson's Disease]
2010     Andalusian Health Technology Assessment Area (AETSA) [Deep brain stimulation in the treatment of depressive and obsessive-complusive disorders]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep brain stimulation in patients with treatment-resistant depressive disorder, obsessive compulsive disorder and Tourette syndrome]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep brain stimulation for Parkinson's disease]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Deep anterior lamellar keratoplasty in keratoconus]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decitabine - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany]
2008     Andalusian Health Technology Assessment Area (AETSA) [Decision making tool for patients with non valvular atrial fibrillation]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Decision Making and Safety Issues in Health Services and Technologies]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid knee endoprosthesis]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for biomarker tests in breast cancer - Addendum to Commission D14-01]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Decision aid for amputations in diabetic foot syndrome - Rapid Report]
2010     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Decentralized cooperation for development in health and environment: Assessment of barriers and opportunities]
2011     Committee for New Health Technology Assessment (CNHTA) [Debridement using hydrosurgery system]
2012     Haute Autorite de sante (HAS) [Day surgery: an overview]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Day surgery: a systematic overview]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Data-supported timely management in cooperation with a centre for telemedicine for patients with advanced cardiac failure - rapid report]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir/ombitasvir/paritaprevir/ritonavir (Addendum to Commissions A15-03 and A15-04)]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dasabuvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darvadstrocel (perianal fistulas in Crohn disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) - Addendum to Commission A20-43]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Daratumumab for relapsed or refractory multiple myeloma]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, stem cell transplant unsuitable) - Addendum to Commission A20-14]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (newly diagnosed multiple myeloma, stem cell transplant suitable) - Addendum to Commission A20-15]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A21-101]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A18-66]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) - Addendum to Commission A17-40]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin (type 2 diabetes mellitus) - Addendum to Commission A19-52]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin/metformin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus) - Addendum to Commission A19-53]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 2 diabetes mellitus in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (kidney disease) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure) - Benefit assessment according to §35a Social Code Book V]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure) - Addendum to Commission A20-113]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Danish stroke treatment]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Damoctocog alfa (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Dalfampridine (ampyra) in multiple sclerosis patients]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Daily hemodialysis vs conventional hemodialysis: systematic review of clinical results and economic analysis]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Daily hemodialysis vs conventional hemodialysis: systematic review of clinical results and economic analysis]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daclatasvir - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib/trametinib - Addendum to Commissions A15-39 and A15-40]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dabrafenib plus trametinib for advanced melanoma]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (new therapeutic indication): benefit assessment according to §35a Social Code Book V]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (melanoma) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib (melanoma) - Addendum to Commission A18-59]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dabrafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2011     The Swedish Council on Health Technology Assessment (SBU) [Dabigatran to prevent stroke in patients with atrial fibrillation]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery]
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei]
2020     National Committee for Technology Incorporation (CONITEC) [Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma]
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Cytoreductive surgery and intraperitoneal chemotherapy (HIPEC or EPIC) in patients with colorectal adenocarcinoma and peritoneal carcinomatosis.]
2020     National Committee for Technology Incorporation (CONITEC) [Cytoreductive surgery (peritonectomy) with hyperthermic intraperitoneal chemotherapy (HIPEC)]
2012     Finnish Office for Health Care Technology Assessment (Finohta) [Cystatin C in the (early) diagnosis of renal failure]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [CYD tetravalent dengue vaccine]